Triptans elicit vasoconstriction in many cephalic vessels by stimulation of vascular 5-HT
1B receptors (
40,
41,
56,
61,
80,
95,
128,
131), whereas 5-HT
1D and 5-HT
1F receptors do not appear to be involved (
10,
20,
104) despite the detection of 5-HT
1D and 5-HT
1F receptor mRNA in blood vessels (
5,
11,
51,
138). Because 5-HT
1B receptors are also localized on noncranial vessels, some systemic and coronary vasoconstriction is unavoidable (
29,
78,
79,
84,
85). Triptan-activated vascular 5-HT
1B receptors are thus involved in both the therapeutic and cardiovascular side effects of migraine therapy.
Vascular 5-HT1B Receptor-Effector Coupling
The precise signaling pathways that generate vasoconstriction following 5-HT
1B receptor stimulation have not been fully elucidated. This is illustrated in
Figure 21-1, in which the most clearly established components of the signaling pathways (shown in bold) are inhibition of adenylate cyclase and opening of sarcolemmal voltage-gated L-type Ca
2+ channels to allow Ca
2+ influx (
1,
8,
33,
88,
93,
121,
122).
Following vascular 5-HT
1B receptor stimulation, the pertussis toxin (PTx)-sensitive Gi/o heterotrimer splits into Gi
α monomer and G
βγ dimer (
66), and subsequent inhibition of adenylate cyclase and activation of Ca
2+ influx via L-type voltage-gated Ca
2+ channels occur concomitantly (
33,
121). Gi
α mediates adenylate cyclase inhibition (
33), but the signaling pathway that links Gi/o to L-type voltage-gated Ca
2+ channel opening is unclear, although a role for the separated G
βγ subunits has been suggested (
19,
42,
66). The subsequent increases in intracellular free Ca
2+ concentrations allow Ca
2+binding to calmodulin and myosin light chain kinase (MLCK) activation. MLCK phosphorylates the 20-kDa fragment of myosin light chain, which in turn stimulates actin-myosin APTase, actin-myosin cross-bridging, and the development of force (
49,
118; see
Fig. 1). The requirement of extracellular Ca
2+ influx via L-type voltage-gated Ca
2+ channels on 5-HT
1B receptor-mediated vasoconstriction is not uniform in all blood vessels that express the receptor (
8,
33,
48,
121).
A major characteristic of triptan-induced vasoconstriction is that precontraction is required in several but not all systemic blood vessels (
141). In the absence of precontraction, triptan-induced contractile responses do not occur in rabbit iliac (
142), mesenteric (
18), renal (
17), ear artery (
93), or canine mesenteric artery (
116), for example. However, precontraction is not required for triptan-induced vasoconstriction in human and nonhuman cerebral arteries (
8,
86,
95,
96,
104,
108) canine (
57), and rabbit (
126,
130) saphenous vein, canine (
26,
127), and human (
22,
84,
85)
coronary arteries. A clear explanation for these differences has not been provided thus far, although cross-talk (
125) or synergy with other second-messenger responses that favor the sensitivity to (
51), or availability of, intracellular free Ca
2+ ions to the contractile proteins, such as Gq-coupled receptors, has been suggested (
31).
Whether Gi
α-mediated inhibition of adenylate cyclase may be directly associated with vasoconstriction remains unclear (
1), but amplified mitogen-activated protein kinase (MAPK) has been suggested (
51) to play a role.
Calcitonin gene-related peptide (CGRP), which may be released from trigeminal sensory neurons during a migraine attack (
34,
35) is a potent vasodilator in systemic and cranial blood vessels (
6,
27,
135). When CGRP activates its vascular receptors (
67), the receptor complex formed (
89,
102) couples to the Gs
α subunit, which in turn activates adenylate cyclase (
52,
62,
67,
68). CGRP-evoked increases in cyclic adenosine monophosphate (cAMP) levels activate cAMP-dependent protein kinase A isozymes (
123), which cause relaxation by lowering both intracellular free Ca
2+ concentrations and the sensitivity of the contractile elements to Ca
2+.
Besides promoting increases in intracellular calcium concentrations, triptans may therefore be expected to partly reduce CGRP-induced vasodilatation by a postjunctional mechanism of inhibiting CGRP-activated adenylate cyclase following vascular 5-HT
1B receptor stimulation (
115,
136,
137), in addition to the well-established prejunctional mechanism of inhibiting CGRP release from sensory afferent nerve terminals (
14,
77,
91).
Other signaling pathways have been investigated in triptan-induced vasoconstrictor responses. The mixed phosphatidylinositol 3-kinase (PI3K) and MLCK inhibitor, wortmannin, and the MAPK inhibitor, U01296, independently inhibited 5-HT
1B-mediated contractile responses in rabbit renal artery (
51), suggesting the involvement of MAPK and PI3K pathways. The MAPK pathway is generally associated with cell growth and mitogenesis (
82,
83), but is also suspected to be able to modulate smooth muscle contractility (
87). For receptors coupled to PTx-sensitive Gi/o proteins, which include 5-HT
1B receptors, MAPK activation occurs via a PKC-independent activation of Ras (
71) and Raf (
107) initiated by release of
βγ subunits from the heterotrimeric Gi/o proteins (
23,
66,
70) (see
Fig. 21-1). Upon activation, MAPK translocates to the nucleus where it phosphorylates transcription factors leading to subsequent mitogenesis (
90). It is unknown whether phospholipase C activation is involved in 5-HT
1B receptor-mediated vasoconstriction, but a possible role for phospholipase D has been suggested (
50) being dependent on the extracellular Ca
2+ concentration and protein kinase C (
50). There is no clear-cut evidence for the involvement of inositol phosphate generation associated with intracellular Ca
2+ release in 5-HT
1B receptor-mediated vasoconstriction (see
Fig. 21-1).
Only gold members can continue reading.
Log In or
Register to continue
Related
Full access? Get Clinical Tree